Technical Analysis for LNTH - Lantheus Holdings, Inc.

Grade Last Price % Change Price Change
C 81.10 1.88% 1.50
LNTH closed up 1.88 percent on Thursday, May 16, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Outside Day Range Expansion 1.88%
Wide Bands Range Expansion 1.88%
Overbought Stochastic Strength 1.88%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 22 hours ago
Up 1% about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
Rose Above Previous Day's High 2 days ago
Outside Day 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lantheus Holdings, Inc. Description

Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease Chemical Elements Prostate Cancer Heart Failure Medical Imaging Stroke Medical Physics Artery Perfusion Artery Disease Imaging Agent Peripheral Vascular Disease Radiopharmaceuticals Congestive Heart Failure Coronary Artery Disease Gallium Neuron Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging

Is LNTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 100.48
52 Week Low 50.2
Average Volume 907,374
200-Day Moving Average 64.81
50-Day Moving Average 64.86
20-Day Moving Average 71.87
10-Day Moving Average 77.08
Average True Range 2.48
RSI (14) 78.26
ADX 54.47
+DI 40.08
-DI 6.36
Chandelier Exit (Long, 3 ATRs) 73.80
Chandelier Exit (Short, 3 ATRs) 68.91
Upper Bollinger Bands 84.10
Lower Bollinger Band 59.64
Percent B (%b) 0.88
BandWidth 34.04
MACD Line 4.55
MACD Signal Line 3.88
MACD Histogram 0.6642
Fundamentals Value
Market Cap 5.55 Billion
Num Shares 68.5 Million
EPS 1.50
Price-to-Earnings (P/E) Ratio 54.07
Price-to-Sales 3.21
Price-to-Book 5.51
PEG Ratio 0.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 83.79
Resistance 3 (R3) 83.54 82.39 83.34
Resistance 2 (R2) 82.39 81.71 82.52 83.19
Resistance 1 (R1) 81.75 81.29 82.07 82.00 83.04
Pivot Point 80.60 80.60 80.76 80.73 80.60
Support 1 (S1) 79.96 79.92 80.28 80.20 79.16
Support 2 (S2) 78.81 79.50 78.94 79.01
Support 3 (S3) 78.17 78.81 78.86
Support 4 (S4) 78.41